• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经纤维瘤病2型相关神经鞘瘤病的临床严重程度分级

Clinical severity grading of NF2-related schwannomatosis.

作者信息

Lawson McLean Anna C, Löschner Denise, Farschtschi Said, Dengler Nora F, Rosahl Steffen K

机构信息

Department of Neurosurgery, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.

Department of Neurosurgery, Helios Klinikum Erfurt, Erfurt, Germany.

出版信息

Orphanet J Rare Dis. 2025 Jan 6;20(1):4. doi: 10.1186/s13023-024-03512-3.

DOI:10.1186/s13023-024-03512-3
PMID:39762911
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11706147/
Abstract

BACKGROUND

NF2-related schwannomatosis (NF2) is associated with various tumors of the central and peripheral nervous system. There is a wide range of disabilities these patients may suffer from and there is no validated clinical classification for disease severity. We propose a clinical classification consisting of three severity grades to assist in patient management.

METHODS

Patient records from 168 patients were screened for most common diagnoses with severe impact on everyday tasks, social interactions and life expectancy. Eight main categories were identified. One point was assigned to each category. Three severity grades were differentiated as follows: grade 1 (mild NF2): 0 points; grade 2 (moderate NF2): < 3 points; grade 3 (severe NF2): ≥ 3 points. This grading system was then evaluated with respect to inter-rater reliability and clinical significance.

RESULTS

The patients were grouped according to our new clinical grading system into grade 1 in 48% (n = 80), grade 2 in 43% (n = 72), and grade 3 in 10% of patients (n = 16). There was substantial inter-rater reliability between 3 raters with different levels of clinical experience (Fleiss' kappa = 0.62). The severity grades correlated significantly with hospitalization, number of operations and dependency on implants (such as cochlear implant, auditory brain-stem implants or ventriculoperitoneal shunts).

CONCLUSIONS

Clinical disease severity of NF2 patients is reflected in a simplified and rater-independent score with three grades. The score facilitates communication for medical personnel of varying experience and backgrounds, and adds a clinical tool to decision-making and research.

摘要

背景

与神经纤维瘤病2型(NF2)相关的神经鞘瘤病与中枢和周围神经系统的各种肿瘤有关。这些患者可能会出现各种各样的残疾,并且对于疾病严重程度没有经过验证的临床分类。我们提出了一种由三个严重程度等级组成的临床分类,以协助患者管理。

方法

对168例患者的病历进行筛查,以找出对日常任务、社交互动和预期寿命有严重影响的最常见诊断。确定了八个主要类别。每个类别给予一分。区分出三个严重程度等级如下:1级(轻度NF2):0分;2级(中度NF2):<3分;3级(重度NF2):≥3分。然后对该分级系统的评分者间可靠性和临床意义进行评估。

结果

根据我们新的临床分级系统,患者被分为1级的占48%(n = 80),2级的占43%(n = 72),3级的占10%(n = 16)。三位具有不同临床经验水平的评分者之间具有较高的评分者间可靠性(Fleiss' kappa = 0.62)。严重程度等级与住院情况、手术次数以及对植入物(如人工耳蜗、听觉脑干植入物或脑室腹腔分流管)的依赖程度显著相关。

结论

NF2患者的临床疾病严重程度通过一个简化的、与评分者无关的三分制评分来体现。该评分便于不同经验和背景的医务人员进行沟通,并为决策和研究增加了一种临床工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1095/11706147/fafbb9658299/13023_2024_3512_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1095/11706147/50739e259f73/13023_2024_3512_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1095/11706147/87af23319144/13023_2024_3512_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1095/11706147/fafbb9658299/13023_2024_3512_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1095/11706147/50739e259f73/13023_2024_3512_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1095/11706147/87af23319144/13023_2024_3512_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1095/11706147/fafbb9658299/13023_2024_3512_Fig3_HTML.jpg

相似文献

1
Clinical severity grading of NF2-related schwannomatosis.神经纤维瘤病2型相关神经鞘瘤病的临床严重程度分级
Orphanet J Rare Dis. 2025 Jan 6;20(1):4. doi: 10.1186/s13023-024-03512-3.
2
Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.65例施万细胞瘤病患者的脊髓神经鞘瘤与831例孤立性神经鞘瘤及102例2型神经纤维瘤病患者的临床特征比较:单机构回顾性研究
J Neurosurg Spine. 2016 Jan;24(1):145-54. doi: 10.3171/2015.3.SPINE141145. Epub 2015 Sep 25.
3
Distinctive low epidermal nerve fiber density in schwannomatosis patients provides a major parameter for diagnosis and differential diagnosis.神经鞘瘤病患者的表皮神经纤维密度明显降低,为诊断和鉴别诊断提供了主要参数。
Brain Pathol. 2020 Mar;30(2):386-391. doi: 10.1111/bpa.12780. Epub 2019 Sep 12.
4
Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.多发性非真皮神经鞘瘤患者中 NF2 嵌合体和神经鞘瘤病的表型和基因型重叠。
Hum Genet. 2018 Jul;137(6-7):543-552. doi: 10.1007/s00439-018-1909-9. Epub 2018 Jul 13.
5
Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2-related schwannomatosis.与2型神经纤维瘤病相关的神经鞘瘤病高危个体的基因检测、筛查及临床管理更新方案
Clin Genet. 2023 May;103(5):540-552. doi: 10.1111/cge.14310. Epub 2023 Mar 15.
6
Neurofibromatosis type 2-related schwannomatosis - An update.2型神经纤维瘤病相关的神经鞘瘤病——最新进展
Semin Pediatr Neurol. 2024 Dec;52:101171. doi: 10.1016/j.spen.2024.101171. Epub 2024 Nov 9.
7
Multiple schwannomas: schwannomatosis or neurofibromatosis type 2?多发性神经鞘瘤:是施万细胞瘤病还是2型神经纤维瘤病?
J Neurosurg. 1998 Jul;89(1):36-41. doi: 10.3171/jns.1998.89.1.0036.
8
Schwannomatosis: a genetic and epidemiological study.神经鞘瘤病:一项遗传学和流行病学研究。
J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1215-1219. doi: 10.1136/jnnp-2018-318538. Epub 2018 Jun 16.
9
Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.针对神经纤维瘤病 2 型、雪旺细胞瘤病和脑膜瘤病的靶向下一代测序进行鉴别诊断。
Neuro Oncol. 2018 Jun 18;20(7):917-929. doi: 10.1093/neuonc/noy009.
10
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.成人神经纤维瘤病患者全身肿瘤负担的定量评估。
PLoS One. 2012;7(4):e35711. doi: 10.1371/journal.pone.0035711. Epub 2012 Apr 27.

本文引用的文献

1
The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.神经纤维瘤病 2 生活质量影响问卷德语文本与抑郁严重程度和医生报告的疾病严重程度相关。
Orphanet J Rare Dis. 2023 Jan 6;18(1):3. doi: 10.1186/s13023-022-02607-z.
2
The Neurofibromatoses.神经纤维瘤病。
Dtsch Arztebl Int. 2020 May 15;117(20):354-360. doi: 10.3238/arztebl.2020.0354.
3
Association between patient-reported outcomes and objective disease indices in people with NF2.
神经纤维瘤病2型患者自我报告结果与客观疾病指标之间的关联。
Neurol Clin Pract. 2019 Aug;9(4):322-329. doi: 10.1212/CPJ.0000000000000648.
4
Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation.贝伐单抗治疗2型神经纤维瘤病(NF2)相关前庭神经鞘瘤:全国性的协调给药方法及前瞻性评估
Neurooncol Pract. 2016 Dec;3(4):281-289. doi: 10.1093/nop/npv065. Epub 2016 Jan 7.
5
Genetic Severity Score predicts clinical phenotype in NF2.遗传严重程度评分可预测 NF2 的临床表型。
J Med Genet. 2017 Oct;54(10):657-664. doi: 10.1136/jmedgenet-2017-104519. Epub 2017 Aug 28.
6
Self-reported benefit, sound perception, and quality-of-life in patients with auditory brainstem implants (ABIs).听觉脑干植入(ABI)患者的自我报告获益、听觉感知及生活质量
Acta Otolaryngol. 2016;136(1):62-7. doi: 10.3109/00016489.2015.1079925. Epub 2015 Oct 1.
7
Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.288例2型神经纤维瘤病患者生活质量的纵向评估。
J Neurol. 2014 May;261(5):963-9. doi: 10.1007/s00415-014-7303-1. Epub 2014 Mar 12.
8
The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2.神经纤维瘤病2型特定疾病生活质量问卷(NFTI-QOL)
J Neurol Surg B Skull Base. 2012 Apr;73(2):104-11. doi: 10.1055/s-0032-1301396.
9
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.成人神经纤维瘤病患者全身肿瘤负担的定量评估。
PLoS One. 2012;7(4):e35711. doi: 10.1371/journal.pone.0035711. Epub 2012 Apr 27.
10
Assessment of immobility hazards.
Home Care Provid. 1998 Aug;3(4):189-91. doi: 10.1016/s1084-628x(98)90124-1.